Senti Biosciences Inc (NASDAQ: SNTI) has experienced a decline in its stock price by -20.00 compared to its previous closing price of 5.00. However, the company has seen a gain of 0.76% in its stock price over the last five trading days. globenewswire.com reported 2025-04-28 that Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 Dose Finding completed with no dose limiting toxicities and preliminary recommended Phase 2 dose (RP2D) identified 5 of 7 best overall response evaluable patients achieved ORR (3 CR, 1 CRh and 1 morphologic leukemia-free state) across all dose cohorts, including 1 CR and 1 CRh in 3 patients in preliminary RP2D cohort 4 of 4 cCR patients were measurable residual disease (MRD) negative as assessed by local standard of care Early deep responses with SENTI-202 noted across dose levels with all cCRs ongoing as of the data cut and longest durability of 8+ months Company to host webcast to discuss the new Phase 1 SENTI-202 data today, April 28th at 8:30 AM ET; Register Here Announces certain preliminary first quarter 2025 financial results and provides pipeline update SOUTH SAN FRANCISCO, Calif., April 28, 2025 (GLOBE NEWSWIRE) — Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported additional positive preliminary data from a Phase 1 clinical trial of SENTI-202, a potential first-in-class off-the-shelf Logic Gated selective CD33 OR FLT3 NOT EMCN chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy, for the treatment of relapsed/refractory (R/R) hematologic malignancies including acute myeloid leukemia (“AML”).
Is It Worth Investing in Senti Biosciences Inc (NASDAQ: SNTI) Right Now?
The 36-month beta value for SNTI is also noteworthy at 2.20. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for SNTI is 7.88M, and at present, short sellers hold a 0.88% of that float. The average trading volume of SNTI on April 28, 2025 was 31.00K shares.
SNTI’s Market Performance
The stock of Senti Biosciences Inc (SNTI) has seen a 0.76% increase in the past week, with a 20.28% rise in the past month, and a -11.50% fall in the past quarter. The volatility ratio for the week is 9.87%, and the volatility levels for the past 30 days are at 11.19% for SNTI. The simple moving average for the past 20 days is 11.14% for SNTI’s stock, with a 22.84% simple moving average for the past 200 days.
Analysts’ Opinion of SNTI
Many brokerage firms have already submitted their reports for SNTI stocks, with Morgan Stanley repeating the rating for SNTI by listing it as a “Equal-Weight.” The predicted price for SNTI in the upcoming period, according to Morgan Stanley is $7.50 based on the research report published on October 07, 2022 of the previous year 2022.
SNTI Trading at 11.47% from the 50-Day Moving Average
After a stumble in the market that brought SNTI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -76.39% of loss for the given period.
Volatility was left at 11.19%, however, over the last 30 days, the volatility rate increased by 9.87%, as shares surge +16.91% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.25% lower at present.
During the last 5 trading sessions, SNTI rose by +1.01%, which changed the moving average for the period of 200-days by +29.35% in comparison to the 20-day moving average, which settled at $3.60. In addition, Senti Biosciences Inc saw 13.96% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SNTI starting from Lu Timothy K, who sale 3,922 shares at the price of $4.07 back on Feb 04 ’25. After this action, Lu Timothy K now owns 82,627 shares of Senti Biosciences Inc, valued at $15,963 using the latest closing price.
Lu Timothy K, the CEO of Senti Biosciences Inc, sale 545 shares at $4.36 during a trade that took place back on Feb 06 ’25, which means that Lu Timothy K is holding 82,082 shares at $2,376 based on the most recent closing price.
Stock Fundamentals for SNTI
Current profitability levels for the company are sitting at:
- -10.42 for the present operating margin
The net margin for Senti Biosciences Inc stands at -9.01. The total capital return value is set at -0.72. Equity return is now at value -89.73, with -48.58 for asset returns.
Based on Senti Biosciences Inc (SNTI), the company’s capital structure generated 0.57 points at debt to capital in total, while cash flow to debt ratio is standing at -1.23.
Currently, EBITDA for the company is -61.04 million with net debt to EBITDA at 0.33. When we switch over and look at the enterprise to sales, we see a ratio of 15.23. The receivables turnover for the company is 3.24for trailing twelve months and the total asset turnover is 0.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.49.
Conclusion
In summary, Senti Biosciences Inc (SNTI) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
